Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;306(5):1665-1672.
doi: 10.1007/s00404-022-06527-y. Epub 2022 Mar 31.

The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer

Affiliations

The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer

Friederike Luise Rawert et al. Arch Gynecol Obstet. 2022 Nov.

Abstract

Purpose: Achieving complete cytoreduction (CCR) is crucial for a patient's prognosis with advanced epithelial ovarian cancer (EOC). So far, prognostic predictors have failed to predict surgical outcome after neoadjuvant chemotherapy (NACT). In clinical trials, scores were used to predict operability in recurrent ovarian cancer (Harter et al. in N Engl J Med 385(23):2123-2131, 2021) but there is no known prediction score for CCR after NACT. The Peritoneal Cancer Index (PCI) is an established tool to predict surgical outcome in primary setting (Lampe et al. in 25:135-144, 2015). We now examined the predictive power of the PCI to achieve CCR after NACT.

Methods: In this single-center study, the data of patients with advanced stage EOC (FIGO > IIIb) treated between 01/2015 and 12/2020 were analyzed retrospectively. Inclusion criteria were a mandatory staging laparoscopy, a PCI score > 25, and NACT. CT scans were analyzed in blinded fashion according to RECIST criteria (Borgani et al. in 237; 93-99, 2019) Reaction of PCI after NACT was compared with the analysis of radiologic imaging and CA-125 levels.

Results: Three hundred and sixteen patients were screened, 62 were treated with NACT, and 23 were included in our analysis. 87% of cases presented with an FIGO IIIc stadium. The reduction of PCI itself after NACT showed to be the most powerful predictor for achieving CCR. The reduction of the initial PCI score by minimum of 8.5 points was a better predictor for CCR than reaching a PCI < 25. In contrast to data deriving from patients undergoing primary debulking surgery (PDS), we found a PCI of 17, rather than 25, to be a more valuable cut-off for CCR in neoadjuvant-treated patients.

Conclusion: The extend of PCI reduction after NACT is a better predictor for achieving CCR compared with CA125 levels and radiologic imaging. The PCI must be assessed differently in neoadjuvant setting than in a primary situation. CCR was most likely for a post-NACT PCI < 17.

Keywords: Complete cytoreductive surgery; Neoadjuvant chemotherapy; Ovarian cancer; PCI score; Peritoneal Carcinomatosis Index; Prognostic score.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Patient screening process
Fig. 2
Fig. 2
Patient’s level of tumor marker CA-125 before and after neoadjuvant CTX (logarithmic scale)
Fig. 3
Fig. 3
PCI score before and after neoadjuvant CTX
Fig. 4
Fig. 4
ROC PCI after NACT no complete cytoreduction (non-CCR)
Fig. 5
Fig. 5
ROC PCI reduction complete cytoreduction (CCR)

References

    1. Harter P, Sehouli J, Vergote I, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2021;385(23):2123–2131. doi: 10.1056/nejmoa2103294. - DOI - PubMed
    1. Lampe B, Kroll N, Piso P, Forner DM, Mallmann P. Prognostic significance of sugarbaker’s peritoneal cancer index for the operability of ovarian carcinoma. Int J Gynecol Cancer. 2015;25(1):135–144. doi: 10.1097/IGC.0000000000000327. - DOI - PubMed
    1. Bogani G, Matteucci L, Tamberi S, et al. RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy. Eur J Obstet Gynecol Reprod Biol. 2019;237:93–99. doi: 10.1016/j.ejogrb.2019.04.007. - DOI - PubMed
    1. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296. doi: 10.3322/caac.21456. - DOI - PMC - PubMed
    1. Leitlinienprogramm Onkologie. S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 4.0, AWMF-Registriernummer: 032/035OL. 2020:1–153. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downlo....

MeSH terms